Literature DB >> 35854342

Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

Thomas E Bartlett1, Iona Evans2, Allison Jones2, James E Barrett2,3,4, Shaun Haran2, Daniel Reisel2, Kiriaki Papaikonomou5, Louise Jones6, Chiara Herzog3,4, Nora Pashayan7, Bruno M Simões8, Robert B Clarke8, D Gareth Evans9, Talayeh S Ghezelayagh10,11, Sakthivignesh Ponandai-Srinivasan5, Nageswara R Boggavarapu5, Parameswaran G Lalitkumar5, Sacha J Howell8,12, Rosa Ana Risques10, Angelique Flöter Rådestad5, Louis Dubeau13, Kristina Gemzell-Danielsson5, Martin Widschwendter14,15,16,17.   

Abstract

Entities:  

Year:  2022        PMID: 35854342      PMCID: PMC9295457          DOI: 10.1186/s13073-022-01086-y

Source DB:  PubMed          Journal:  Genome Med        ISSN: 1756-994X            Impact factor:   15.266


× No keyword cloud information.
Correction: Genome Med 14, 64 (2022) https://doi.org/10.1186/s13073-022-01063-5 Following publication of the original article [1], an error was identified in the Funding section. The section currently reads: This study was funded by the European Union’s Horizon 2020 European Research Council Programme, H2020 BRCA-ERC under Grant Agreement No. 742432 as well as the charity The Eve Appeal (https://eveappeal.org.uk). Additional aspects of the study were supported by the Swedish Research Council Grant # 2017-00932, 2012-02961, Region Stockholm and Karolinska Institutet (ALF), Cancerfonden (Grant no. CAN 2016/696), and Radiumhem- mets Forskningsfonder (# 154143, 184033) as well as by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The work carried out by TEB was supported by MRC grant MR/P014070/1. It should read: This study was funded by the European Union’s Horizon 2020 European Research Council Programme, H2020 BRCA-ERC under Grant Agreement No. 742432 as well as the charity The Eve Appeal (https://eveappeal.org.uk). Additional aspects of the study were supported by the Swedish Research Council Grant # 2017-00932, 2012-02961, Region Stockholm and Karolinska Institutet (ALF), Cancerfonden (Grant no. CAN 2016/696), and Radiumhem- mets Forskningsfonder (# 154143, 184033) as well as by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215-20007). The work carried out by TEB was supported by MRC grant MR/P014070/1. Clinical trial 3 was supported by Breast Cancer Now [Grant Ref no: 2014May-CR003]” The original article [1] has been corrected.
  1 in total

1.  Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.

Authors:  Thomas E Bartlett; Iona Evans; Allison Jones; James E Barrett; Shaun Haran; Daniel Reisel; Kiriaki Papaikonomou; Louise Jones; Chiara Herzog; Nora Pashayan; Bruno M Simões; Robert B Clarke; D Gareth Evans; Talayeh S Ghezelayagh; Sakthivignesh Ponandai-Srinivasan; Nageswara R Boggavarapu; Parameswaran G Lalitkumar; Sacha J Howell; Rosa Ana Risques; Angelique Flöter Rådestad; Louis Dubeau; Kristina Gemzell-Danielsson; Martin Widschwendter
Journal:  Genome Med       Date:  2022-06-15       Impact factor: 15.266

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.